Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04634149 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04634149 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 16 participants.
The verdict
NCT04634149, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effect of impaired liver function on the drug levels, safety, and tolerability of BMS-986036 in participants with moderate and severe liver impairment. Results from this study will be used to determine whether dose adjustment is required for patients with decreased liver function.
Interventions
- DRUG BMS-986036
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-11-23 |
| Est. Completion | 2022-06-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04634149
The ClinicalTrials.gov registry entry for NCT04634149 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-986036 is the first listed.
NCT04634149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04634149 about?
NCT04634149 is a clinical study titled "A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment". The purpose of this study is to investigate the effect of impaired liver function on the drug levels, safety, and tolerability of BMS-986036 in participants with moderate and severe liver impairment. Results from this study will be used to determine whether dose adjustment is required for patients w...
What is the current status of trial NCT04634149?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2020-11-23. Estimated completion is 2022-06-02.
What interventions are being tested in trial NCT04634149?
The interventions under investigation include: BMS-986036 (DRUG).
Who is sponsoring clinical trial NCT04634149?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.